Dr. Ernest Mario has served as Chairman of our Board of Directors since February 2013. He is currently Chairman of Capnia, Inc., a private pharmaceutical company developing novel therapeutic products to treat migraine and allergic rhinitis using a proprietary gas delivery system. He also is a Venture Partner with Pappas Ventures, a Research Triangle Park, NC life science venture capital firm. Dr. Mario served in management at a number of drug companies prior to 1989 when he was named Chief Executive of Glaxo, plc, then the second-largest drug company in the world. Later Dr. Mario led pioneering drug delivery technology company ALZA Corporation until its acquisition by Johnson & Johnson in 2001. He subsequently served as Chairman and CEO of Reliant Pharmaceuticals, Inc. until its acquisition by GlaxoSmithKline in 2007. Dr. Mario serves as a director of Boston Scientific Corporation, Celgene Corporation, TONIX Pharmaceuticals Holdings Corp., Kindred Biosciences Inc. and XenoPort Inc. He is active in numerous educational and healthcare organizations. He is Chairman of the American Foundation for Pharmaceutical Education, a Director of the Gladstone Foundation, and past Chairman of the Duke University Health System. Dr. Mario earned a BS in pharmacy at Rutgers and his MS and PhD in physical sciences at the University of Rhode Island. He holds honorary doctorates from URI and Rutgers, the latter of which in 2001 renamed its pharmacy school the Ernest Mario School of Pharmacy. In 2007, he was awarded the Remington Medal by the American Pharmacists’ Association, pharmacy’s highest honor.
Dr. M. Michelle Berrey joined Chimerix in 2012 as Chief Medical Officer (CMO) and was named President and Chief Executive Officer (CEO) in April 2014. Prior to joining Chimerix, Dr. Berrey was CMO at Pharmasset, Inc., a company that focused on the development of nucleotide analogs for the treatment of hepatitis C, from 2007 until its acquisition by Gilead Sciences, Inc. (NASDAQ: GILD) in January 2012. Dr. Berrey's expertise includes the design, early development, medical governance, clinical strategy and product life cycle management of antiviral compounds. Previously, Dr. Berrey served as Vice President, Viral Diseases, Clinical Pharmacology & Discovery Medicine at GlaxoSmithKline, where she was responsible for the early development of compounds for the treatment of HIV, hepatitis viruses and hepatic fibrosis. Dr. Berrey received her MD from the Medical College of Georgia and a Master of Public Health from Emory University. She completed her internship and residency in Internal Medicine at the University of North Carolina at Chapel Hill, and was a Senior Fellow in Infectious Diseases at the University of Washington, Seattle, where she conducted research in HIV transmission and acute HIV infection. She is Board Certified in Internal Medicine and Infectious Diseases.
James M. Daly currently serves as Executive Vice President and Chief Commercial Officer at Incyte Corporation, a biopharmaceutical company, a position he has held since October 2012. Prior to joining Incyte, Mr. Daly served as Senior Vice President of North America Commercial Operations and Global Marketing/Commercial Development at Amgen Inc., a global pharmaceutical company, where he was employed from January 2002 to December 2011. Prior to his employment with Amgen, Mr. Daly was Senior Vice President and General Manager of the Respiratory/Anti-infective business unit at GlaxoSmithKline, where he was employed from June 1985 to December 2001. Mr. Daly is a pharmacist and received his B.S. and M.B.A. degrees from the University of Buffalo, The State University of New York.
Martha Demski has served as one of our directors since 2005. Since August 2011, Ms. Demski has served as Senior Vice President and Chief Financial Officer of Ajinimoto Althea, Inc. (formerly Althea Technologies, Inc.), a fully-integrated contract development and manufacturing organization. From July 2008 to December 2010, Ms. Demski served as the Interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center (SKCC), a non-profit corporation that was engaged in biomedical research. Previously, Ms. Demski served as Vice President and Chief Financial Officer of Vical Incorporated. Ms. Demski currently serves on the board of directors and chairs the audit committee of Adamas Pharmaceuticals, Inc. Ms. Demski also serves as a member of the board, chair of the audit committee and member of the compensation committee of Neothetics, Inc. Additionally Ms. Demski has over 13 years of banking experience with Bank of America and U.S. Trust. Ms. Demski earned a B.A. from Michigan State University and M.B.A. from The University of Chicago Booth School of Business with concentrations in accounting and finance.
Catherine L. Gilliss, PhD, RN, FAAN, currently serves as the Dean and Helene Fuld Health Trust Professor of Nursing at the Duke University School of Nursing and Vice Chancellor for Nursing Affairs at Duke University. Dr. Gilliss was appointed Dean in 2004, and under her leadership, Duke has become one of the top schools of nursing in the nation. While at Duke, Dr. Gilliss has presided over several transformative initiatives, including the approval and implementation of two new doctoral degree programs: the PhD in Nursing degree program and the Doctor of Nursing Practice program. Dr. Gilliss serves as co-director of the federally-funded Graduate Nurse Education Demonstration designed to increase the numbers of advanced practice nurses able to provide care to the growing Medicare population. Dr. Gilliss has also focused on translational science and innovative models of health care delivery, and serves as the Director of the Duke Translational Nursing Institute. From 1998 until 2004, she was a professor and the Dean at the Yale University School of Nursing. Dr. Gilliss has served as President of the National Organization for Nurse Practitioner Faculties and the American Academy of Nursing. She is a member of the North Carolina Institute of Medicine. Dr. Gilliss earned her Masters of Nursing from the Catholic University of America and her PhD from the University of California, San Francisco, where she also completed postdoctoral studies.
John M. Leonard, MD served as the Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie Inc., a global pharmaceutical company, from its spin-out from Abbott Laboratories in January 2013 until retiring from those positions at the end of 2013. Prior to the formation of AbbVie, Dr. Leonard served as Senior Vice President of Global Pharmaceutical Research and Development at Abbott from 2008 to 2012. He has over 30 years of combined experience in medicine, research and management, serving in various roles at Abbott beginning in 1992. Dr. Leonard earned a Bachelor's Degree in Biochemistry from the University of Wisconsin at Madison and a Doctorate in Medicine from Johns Hopkins University in Baltimore, MD. Dr. Leonard completed an Internship and Residency in Internal Medicine at Stanford University Hospital followed by a Postdoctoral Fellowship in Molecular Virology at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
Patrick Machado is a co-founder of Medivation, Inc., a biopharmaceutical company, and has served on its Board of Directors since April 2014. Prior to his retirement in April 2014, Mr. Machado served as Medivation's Chief Financial Officer since its inception in September 2003 and as its Chief Business Officer since December 2009. From 1998 until 2001, Mr. Machado was employed by ProDuct Health, Inc., a privately-held medical device company, as Vice President, Chief Financial Officer and General Counsel from 1998 to 2000, and as Senior Vice President and Chief Financial Officer from 2000 to 2001. From 2001 until 2002, Mr. Machado served as a consultant to Cytyc Corporation, to assist with transitional matters related to Cytyc Corporation's acquisition of ProDuct Health, Inc. Mr. Machado received a J.D. from Harvard Law School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University.
James Niedel joined the Chimerix Board in 2011. Dr. Niedel is a Managing Director of New Leaf Venture Partners, a healthcare technology fund, where he focuses on biopharmaceutical investments. He was one of the founders of New Leaf in 2005, having moved with the healthcare team from the Sprout Group, where he had been a venture partner since 2002. Prior to joining the venture industry, Dr. Niedel was Chief Science and Technology Officer for GlaxoSmithKline and a member of the board of directors of Glaxo Wellcome plc with responsibility for Global Research and Development, Information Technology and Product Strategy. Before joining the pharmaceutical industry, Dr. Niedel was Professor of Medicine and Chief of Clinical Pharmacology at Duke Medical School, where he had completed an Internal Medicine residency and a Hematology-Oncology fellowship. At Duke, he directed a basic research laboratory studying signal transduction, was an editor of J. Biological Chemistry, J. Immunology, Blood and J. Leukocyte Biology and was selected a Searle Scholar. He received MD and PhD (Biochemistry) degrees from the University of Miami and is a Fellow of the Royal College of Physicians (London).
Mr. Renaud currently serves as Chief Executive Officer at RaNA Therapeutics.
Prior to Mr. Renaud’s appointment as Chief Executive Officer at RaNA Therapeutics in December 2014, he served as President and Chief Executive Officer at Idenix Pharmaceuticals since October 2010. Under his leadership, Idenix refocused its drug discovery and development efforts on nucleotide prodrugs to treat hepatitis C virus (HCV), streamlined operations to better enable cross-functional collaboration and employee engagement, which culminated in its acquisition by Merck for $3.85 billion in August 2014. Prior to October 2010, Mr. Renaud served as the Chief Financial Officer of Idenix from the time he joined Idenix in June 2007 and was additionally appointed chief business officer in June 2010. Prior to joining Idenix, Mr. Renaud served as senior vice president and chief financial officer of Keryx Biopharmaceuticals, from February 2006 to May 2007. From 2000 to 2006, Mr. Renaud was a biotechnology equity research analyst at JP Morgan, Schwab Soundview and Bear Stearns. He also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance. Mr. Renaud holds a BA from St. Anselm College and an MBA from the Marshall School of Business at the University of Southern California. Mr. Renaud is currently a board member of PTC Therapeutics and Akebia Therapeutics.
Lisa Ricciardi joined the Board of Chimerix on April 1, 2014. She is currently a member of the Board of Directors of Drug Healthcare Group, PLC in Dublin, Ireland, and was previously a member of the Board of Directors at Sepracor. Ms. Ricciardi serves as a consultant to Davita RX, a full-service pharmacy specializing in renal care. She has previously served as Senior Vice President of Business Development at Medco Health Solutions, Inc., and was a Venture Partner at Essex Woodlands Health Ventures. She also held several senior management positions at Pfizer, including Senior Vice President in the Licensing and Development Division, closing more than 25 transactions with multi-national firms and biotechnology companies, as well as managing several key product launches in the global pharmaceuticals division. Ms. Ricciardi has a broad range of experience in global and specialty pharmaceutical commercial operations, pharmacy benefits, management, and healthcare services. She has successfully collaborated with an extensive network of industry leaders in the United States, Europe and Japan, and she has played a key role at the board and executive levels on strategic transactions and product launches. Ms. Ricciardi earned an MBA from the University of Chicago and a bachelor’s degree from Wesleyan University.